Management of High-Risk Menopause Patients
Identifying High-Risk Patients
- The American College of Obstetricians and Gynecologists identifies absolute contraindications to systemic HRT, including history of breast cancer or hormone-sensitive malignancies, active or history of venous thromboembolism or stroke, coronary heart disease, active liver disease, antiphospholipid syndrome or positive antiphospholipid antibodies, and unexplained abnormal vaginal bleeding 1, 2
- Women who experienced spontaneous coronary artery dissection (SCAD) should avoid HRT, and it should be discontinued if SCAD occurs while on therapy 3
- Women over 60 years of age or more than 10 years past menopause should avoid oral estrogen-containing HRT due to excess stroke risk 1, 3
Non-Hormonal Treatment Algorithm
- Vaginal moisturizers and lubricants reduce genitourinary symptom severity by up to 50% and have no systemic absorption, making them a safe first-line option for high-risk patients 1
- Locally applied vaginal estrogen may be considered in select high-risk patients after careful risk assessment, improving genitourinary symptom severity by 60-80%, but should be avoided in patients with hormone-sensitive cancers 1, 3
- The North American Menopause Society recommends locally applied vaginal estrogen for genitourinary symptoms 1
Special Considerations
- Women with hormone-sensitive cancers should avoid all systemic hormone therapy and consider non-hormonal options like SSRIs, gabapentin, and vaginal moisturizers 1, 3
- Women with non-hormone-sensitive cancers who develop vasomotor symptoms may consider HRT after oncology consultation, but should re-evaluate at the average age of menopause (51 years) 1
Osteoporosis Prevention
- The American College of Obstetricians and Gynecologists recommends considering alternative therapies for osteoporosis prevention, such as bisphosphonates, denosumab, and selective estrogen receptor modulators (SERMs), rather than using HRT solely for this indication 1, 4
- The U.S. Preventive Services Task Force gives a Grade D recommendation against routine HRT use for prevention of chronic conditions, including osteoporosis 4